National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI

The MERIT Award

Page Options
Print This Page  Print This Page
E-Mail This Document  E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
NCI Highlights
Report to Nation Finds Declines in Cancer Incidence, Death Rates

The Cancer Genome Atlas Reports Brain Tumors Study

NCI Research Coding and Reporting

NCI Launches Community Cancer Centers Pilot

The Nation's Investment in Cancer Research FY 2009

NCI Training and Career Development Inventory

New MERIT Award Winners Announced

caBIG: Connecting the Cancer Community

NCI Participation in the NIH Roadmap

Past Highlights
MERIT Award Recipient: Pier Paolo Pandolfi, M.D., Ph.D.

Pier Paolo Pandolfi, MD, PhD   Sponsoring NCI Division:   Division of Cancer Biology (DCB)
Grant Number: 2 R37 CA71692-10
Award Approved: February, 2006
Institution: Memorial Sloan-Kettering Cancer Center, New York, NY
Department: Molecular & Developmental Biology
Scientific Abstract (CRISP)
http://www.mskcc.org/mskcc/html/10345.cfm
Literature Search on PubMed

PML, PLZF and NPM in the Molecular Pathogenesis of APL

This application focuses on the role of the normal proteins involved in the pathogenesis of APL following the working hypothesis that these genes/proteins may participate in tumorigenesis at large. The focus of this grant is therefore not solely APL per se, but rather how these proteins would participate in tumor suppression and oncogenesis at large. Testing this working hypothesis has been so far rewarding since on the basis of this work the "genes of APL" have by now been firmly implicated in the pathogenesis of other forms of cancer, both solid tumors and hemopoietic malignancies. In addition, through this work we are uncovering how these proteins modulate critical tumor suppressive pathways (e.g. ARF-Mdm2-p53 and PTEN-PI3K-AKT ones), which are universally deregulated in human cancer. In a nutshell, this project tests the provocative hypothesis that functional or physical deregulation/disruption of "leukemia" genes might be extremely relevant to pathogenesis of tumors of diverse histological origins.


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov